Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pfizer’s Paxlovid Listed in MHLW’s COVID-19 Guide
March 3, 2022
- Yervoy Infusion Time Changed for Melanoma: Label Update
March 2, 2022
- Japan Cabinet OKs Draft Bill to Amend PMD Law
March 2, 2022
- Pfizer’s Paxlovid Can Now Be Used Across Japan on In-Hospital Dispensing
March 1, 2022
- Govt Council OKs Draft Policy to Strengthen Vaccine R&D, Establish SCARDA
March 1, 2022
- Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
- 7 Drugs to Be Eligible for Health Coverage for Fertility Treatment
March 1, 2022
- Bayer’s Finerenone, Samsca Prodrug, Chugai Bispecific and More Clear PAFSC Review
February 28, 2022
- MHLW Approves Label Expansions for Retevmo, Keytruda, Lenvima and More
February 28, 2022
- MHLW OKs 48 More Health Damage Claims for COVID-19 Vaccines
February 28, 2022
- Orphan Tag Given to Soticlestat, Marstacimab, Imfinzi
February 28, 2022
- MHLW Plans FY2022 Discussion over Linking National Health Database with Mortality Data
February 28, 2022
- Japan Pledges US$300 Million Contribution for CEPI
February 28, 2022
- Japan Cabinet OKs Draft Economic Security Bill
February 28, 2022
- Fertility Treatment Indications for 9 Meds to Be Reported to PAFSC Panel on March 9
February 25, 2022
- Therapeutic App for Hypertension Up for PAFSC Review on March 9
February 24, 2022
- Bill to Amend PMD Law Set for Cabinet Approval as Early as March 1
February 24, 2022
- Xevudy Delivery for 80,000 People Begins Ahead of Schedule: Health Minister
February 24, 2022
- No Reasonable Link between COVID-19 Vaccinations and Excess Deaths: MHLW Panels
February 22, 2022
- PMDA Reviewing New Safety Risks for Brilinta, Stocrin, Ofev
February 21, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…